...
首页> 外文期刊>Cancer gene therapy >Cycles of transient high-dose cyclophosphamide administration and intratumoral oncolytic adenovirus vector injection for long-term tumor suppression in Syrian hamsters
【24h】

Cycles of transient high-dose cyclophosphamide administration and intratumoral oncolytic adenovirus vector injection for long-term tumor suppression in Syrian hamsters

机译:短暂高剂量环磷酰胺给药和肿瘤内溶瘤腺病毒载体注射的周期可长期抑制叙利亚仓鼠的肿瘤

获取原文
           

摘要

Immune responses against oncolytic adenovirus (Ad) vectors are thought to limit vector anti-tumor efficacy. With Syrian hamsters, which are immunocompetent and whose tumors and normal tissues are permissive for replication of Ad5-based oncolytic Ad vectors, treating with high-dose cyclophosphamide (CP) to suppress the immune system and exert chemotherapeutic effects enhances Ad vector anti-tumor efficacy. However, long-term CP treatment and immunosuppression can lead to anemia and vector spread to normal tissues. Here, we employed three cycles of transient high-dose CP administration plus intratumoral injection of the oncolytic Ad vector VRX-007 followed by withdrawal of CP. Each cycle lasted 4–6 weeks. This protocol allowed the hamsters to remain healthy so the study could be continued for ~100 days. The tumors were very well suppressed throughout the study. With immunocompetent hamsters, the vector retarded tumor growth initially, but after 3–4 weeks the tumors resumed rapid growth and further injections of vector were ineffective. Preimmunization of the hamsters with Ad5 prevented vector spillover from the tumor to the liver yet still allowed for effective long-term anti-tumor efficacy. Our results suggest that a clinical protocol might be developed with cycles of transient chemotherapy plus intratumoral vector injection to achieve significant anti-tumor efficacy while minimizing the side effects of cytostatic treatment.
机译:对溶瘤腺病毒(Ad)载体的免疫应答被认为限制了载体的抗肿瘤功效。使用具有免疫能力且其肿瘤和正常组织可复制基于Ad5的溶瘤性Ad载体的叙利亚仓鼠,用大剂量环磷酰胺(CP)抑制免疫系统并发挥化学治疗作用可增强Ad载体的抗肿瘤功效。但是,长期的CP治疗和免疫抑制可导致贫血,载体可传播至正常组织。在这里,我们采用了三个周期的瞬时大剂量CP给药加上肿瘤内注射溶瘤性Ad载体VRX-007,然后停药。每个周期持续4-6周。该方案使仓鼠保持健康,因此研究可以持续约100天。在整个研究过程中,肿瘤被很好地抑制。对于具有免疫能力的仓鼠,载体最初会延迟肿瘤的生长,但是在3-4周后,肿瘤恢复了快速生长,进一步注射载体无效。用Ad5对仓鼠进行预免疫可防止载体从肿瘤溢出到肝脏,但仍具有有效的长期抗肿瘤功效。我们的结果表明,可以通过短暂化疗和肿瘤内载体注射的周期来开发临床方案,以实现显着的抗肿瘤功效,同时最大程度地减少细胞抑制治疗的副作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号